Related Experiment Videos
Exacerbation of chronic hepatitis D during interferon alpha administration
A Crosignani1, P Invernizzi, R Ferrari
1Department of Internal Medicine, School of Medicine San Paolo, University of Milan, Italy.
Italian Journal of Gastroenterology and Hepatology
|March 26, 1999
Summary
Hepatitis D patients on interferon alpha experienced severe liver damage, particularly those with cirrhosis. Basal cell layer antibodies may indicate a higher risk for this adverse event.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis D infection poses significant liver disease risks.
- Interferon alpha is a treatment for viral hepatitis.
- Cirrhosis complicates hepatitis D management.
Observation:
- Two of seven chronic hepatitis D patients developed acute liver failure during interferon alpha therapy.
- These patients had moderate to severe hepatitis and cirrhosis without portal hypertension.
- Slow recovery was noted after discontinuing interferon alpha.
Findings:
- Basal cell layer antibodies were present in the two patients who experienced liver impairment.
- Only one of the five patients without liver impairment had these antibodies.
- Severe liver decompensation during interferon alpha treatment for hepatitis D is possible.
Implications:
- Interferon alpha therapy can precipitate severe liver decompensation in some hepatitis D patients.
- Basal cell layer antibodies might be a predictive marker for adverse events.
- Further research is needed to confirm the association between antibodies and adverse outcomes.